RIOXF
Rion Co., Ltd. develops, manufactures, sells, and services particle counters, medical equipment, and environmental equipment in Japan. The company's audiological equipment includes hearing instruments, such as analog and digital BTE, trimmer digital BTE, in-the-ear ready and custom-made, and analog body aid instruments, as well as wireless and waterproof hearing instruments; and medical equipment… Read more
RIOXF (RIOXF) - Net Assets
Latest net assets as of September 2025: $32.56 Billion USD
Based on the latest financial reports, RIOXF (RIOXF) has net assets worth $32.56 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($39.67 Billion) and total liabilities ($7.10 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $32.56 Billion |
| % of Total Assets | 82.1% |
| Annual Growth Rate | 7.17% |
| 5-Year Change | 32.49% |
| 10-Year Change | N/A |
| Growth Volatility | 1.5 |
RIOXF - Net Assets Trend (2020–2025)
This chart illustrates how RIOXF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for RIOXF (2020–2025)
The table below shows the annual net assets of RIOXF from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $31.44 Billion | +7.61% |
| 2024-03-31 | $29.21 Billion | +9.77% |
| 2023-03-31 | $26.61 Billion | +5.23% |
| 2022-03-31 | $25.29 Billion | +6.59% |
| 2021-03-31 | $23.73 Billion | +6.72% |
| 2020-03-31 | $22.23 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to RIOXF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 57.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $22.55 Billion | 71.73% |
| Other Components | $8.89 Billion | 28.27% |
| Total Equity | $31.44 Billion | 100.00% |
RIOXF Competitors by Market Cap
The table below lists competitors of RIOXF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Inspired Entertainment Inc
NASDAQ:INSE
|
$167.31 Million |
|
Tien Phong Securities Corp
VN:ORS
|
$167.38 Million |
|
Shenzhen Bestek Technology Co Ltd
SHE:300822
|
$167.38 Million |
|
Saniona AB
ST:SANION
|
$167.38 Million |
|
Synergie
LSE:0HDQ
|
$167.26 Million |
|
475400
KQ:475400
|
$167.25 Million |
|
CoinShares International Limited
OTCQX:CNSRF
|
$167.17 Million |
|
Shanghai Golden Union Commercial Management Co Ltd
SHG:603682
|
$167.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RIOXF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 29,211,366,000 to 31,435,769,000, a change of 2,224,403,000 (7.6%).
- Net income of 2,859,770,000 contributed positively to equity growth.
- Dividend payments of 738,696,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.86 Billion | +9.1% |
| Dividends Paid | $738.70 Million | -2.35% |
| Other Changes | $103.33 Million | +0.33% |
| Total Change | $- | 7.61% |
Book Value vs Market Value Analysis
This analysis compares RIOXF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-03-31 | $1810.87 | $19.75 | x |
| 2021-03-31 | $1931.15 | $19.75 | x |
| 2022-03-31 | $2057.39 | $19.75 | x |
| 2023-03-31 | $2163.30 | $19.75 | x |
| 2024-03-31 | $2372.88 | $19.75 | x |
| 2025-03-31 | $2551.75 | $19.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RIOXF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.10%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.26%
- • Asset Turnover: 0.71x
- • Equity Multiplier: 1.24x
- Recent ROE (9.10%) is above the historical average (8.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 8.00% | 8.29% | 0.72x | 1.34x | $-443.59 Million |
| 2021 | 6.90% | 8.00% | 0.67x | 1.29x | $-735.64 Million |
| 2022 | 8.82% | 9.85% | 0.68x | 1.31x | $-299.44 Million |
| 2023 | 6.76% | 7.54% | 0.69x | 1.30x | $-861.65 Million |
| 2024 | 9.08% | 10.31% | 0.69x | 1.27x | $-268.76 Million |
| 2025 | 9.10% | 10.26% | 0.71x | 1.24x | $-283.81 Million |
Industry Comparison
This section compares RIOXF's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RIOXF (RIOXF) | $32.56 Billion | 8.00% | 0.22x | $167.29 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |